Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
August 14, 2021 at 14:30 PM EDT
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to $2.4 billion in milestones.
